Compare Citius Pharmaceuticals Inc (CTXR) vs Nutanix Inc (NTNX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs Nutanix Inc — how do they compare? Citius Pharmaceuticals Inc trades at $0.5 (market cap $13.62M), while Nutanix Inc trades at $74.63 (market cap $19.78B). The key difference: Nutanix Inc is far larger — about 1452.3× Citius Pharmaceuticals Inc's market cap, and Nutanix Inc is trading nearer its 52-week high, Citius Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Citius Pharmaceuticals Inc for 17 Days and Nutanix Inc for 17 Days on average.
| CTXR | NTNX | |
|---|---|---|
Market Cap | $13.62M | $19.78B |
Volume | 132,438 | 1,717,619 |
Sector | Health | Technology |
52-Week High | $1.82 | $73.42 |
52-Week Low | $0.48 | $34.41 |
Typical Hold Time | 17 Days | 17 Days |
Enterprise Value | $3.79M | $18.94B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.4994, down 1.73% with a bearish technical signal despite oscillators showing oversold conditions. The company reported $7.1M revenue for the first nine months of 2026 from LYMPHIR commercial sales, but continues to post significant losses with a -651.27% net income margin. Recent news highlights strong commercial momentum for LYMPHIR with 44 institutions ordering the treatment since launch.
The stock presents a high-risk opportunity with analyst consensus strongly bullish (83% buy ratings, $5 price target) but fundamental challenges persist. Key risks include ongoing cash burn and execution of commercial strategy, while potential upside depends on successful LYMPHIR adoption and path to profitability.
Nutanix (NTNX) trades at $74.63, up 1.65% on the day, with a bullish technical signal and strong earnings beats in recent quarters. The company reported robust revenue growth to $2.54B in 2025 and a net income margin of 52.81% in 2026, supported by leadership recognition in Gartner Magic Quadrant reports (GlobeNewsWire, 2026-09-16).
Outlook remains positive with a consensus price target of $76.11, though high valuation ratios like EV/EBITDA of 46.22 and an overbought RSI near 89.09 pose risks. Growth drivers include external storage and AI initiatives, but investor caution is warranted due to competitive pressures and supply-chain constraints noted in recent news (MarketBeat, 2026-09-14).
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About Nutanix Inc
Nutanix, Inc. is a global leader in cloud software and hyperconverged infrastructure (HCI) solutions. The company's platform converges computing, virtualization, and storage into a single, seamless software-defined solution, enabling private, hybrid, and multi-cloud environments. Nutanix helps organizations simplify data center operations, manage their applications across various cloud platforms, and reduce IT complexity, positioning it as a key enabler of modern hybrid cloud strategies.
Read more on NTNX →
